96 related articles for article (PubMed ID: 27758802)
1. In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates.
LeFevre M
Evid Based Med; 2016 Dec; 21(6):228-229. PubMed ID: 27758802
[No Abstract] [Full Text] [Related]
2. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Yusuf S; Lonn E; Pais P; Bosch J; López-Jaramillo P; Zhu J; Xavier D; Avezum A; Leiter LA; Piegas LS; Parkhomenko A; Keltai M; Keltai K; Sliwa K; Chazova I; Peters RJ; Held C; Yusoff K; Lewis BS; Jansky P; Khunti K; Toff WD; Reid CM; Varigos J; Accini JL; McKelvie R; Pogue J; Jung H; Liu L; Diaz R; Dans A; Dagenais G;
N Engl J Med; 2016 May; 374(21):2032-43. PubMed ID: 27039945
[TBL] [Abstract][Full Text] [Related]
3. Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk.
Eaton Md CB
Ann Intern Med; 2016 Jul; 165(2):JC8. PubMed ID: 27429320
[No Abstract] [Full Text] [Related]
4. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
Melian EB; Jarvis B
Drugs; 2002; 62(5):787-816. PubMed ID: 11929332
[TBL] [Abstract][Full Text] [Related]
5. More HOPE for Prevention with Statins.
Cushman WC; Goff DC
N Engl J Med; 2016 May; 374(21):2085-7. PubMed ID: 27039666
[No Abstract] [Full Text] [Related]
6. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
[TBL] [Abstract][Full Text] [Related]
7. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Lonn EM; Bosch J; López-Jaramillo P; Zhu J; Liu L; Pais P; Diaz R; Xavier D; Sliwa K; Dans A; Avezum A; Piegas LS; Keltai K; Keltai M; Chazova I; Peters RJ; Held C; Yusoff K; Lewis BS; Jansky P; Parkhomenko A; Khunti K; Toff WD; Reid CM; Varigos J; Leiter LA; Molina DI; McKelvie R; Pogue J; Wilkinson J; Jung H; Dagenais G; Yusuf S;
N Engl J Med; 2016 May; 374(21):2009-20. PubMed ID: 27041480
[TBL] [Abstract][Full Text] [Related]
8. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
[TBL] [Abstract][Full Text] [Related]
9. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
[TBL] [Abstract][Full Text] [Related]
10. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.
Lonn E; Bosch J; Pogue J; Avezum A; Chazova I; Dans A; Diaz R; Fodor GJ; Held C; Jansky P; Keltai M; Keltai K; Kunti K; Kim JH; Leiter L; Lewis B; Liu L; Lopez-Jaramillo P; Pais P; Parkhomenko A; Peters RJ; Piegas LS; Reid CM; Sliwa K; Toff WD; Varigos J; Xavier D; Yusoff K; Zhu J; Dagenais G; Yusuf S;
Can J Cardiol; 2016 Mar; 32(3):311-8. PubMed ID: 26481083
[TBL] [Abstract][Full Text] [Related]
11. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
[TBL] [Abstract][Full Text] [Related]
12. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ].
Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
MMW Fortschr Med; 2008 Jan; 149 Suppl 4():172-81. PubMed ID: 18402243
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?
Wyatt CM; Chertow GM
Kidney Int; 2016 Sep; 90(3):460-2. PubMed ID: 27521103
[TBL] [Abstract][Full Text] [Related]
14. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
Weber MA; Jamerson K; Bakris GL; Weir MR; Zappe D; Zhang Y; Dahlof B; Velazquez EJ; Pitt B
Lancet; 2013 Feb; 381(9866):537-45. PubMed ID: 23219284
[TBL] [Abstract][Full Text] [Related]
15. Is Statin Monotherapy the Perfect Polypill?
Ridker PM
Circulation; 2016 Jul; 134(2):91-3. PubMed ID: 27400893
[No Abstract] [Full Text] [Related]
16. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.
Mugellini A; Nieswandt V
Expert Opin Pharmacother; 2012 Dec; 13(18):2699-709. PubMed ID: 23170938
[TBL] [Abstract][Full Text] [Related]
17. Hydrochlorothiazide compared to candesartan treatment increases adipose tissue gene expression and circulating levels of serum amyloid A in hypertensive patients.
Palming J; Jansson PA; Renström F; Johansson A; Johansson L; Karlsson C; Lind L; Eriksson JW
Horm Metab Res; 2011 May; 43(5):319-24. PubMed ID: 21332024
[TBL] [Abstract][Full Text] [Related]
18. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.
Neldam S; Forsén B;
Drugs Aging; 2001; 18(3):225-32. PubMed ID: 11302289
[TBL] [Abstract][Full Text] [Related]
20. [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension].
Uen S; Un I; Fimmers R; Vetter H; Mengden T
Dtsch Med Wochenschr; 2007 Jan; 132(3):81-6. PubMed ID: 17219340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
